Diagnosis & Disease Information

Lower mortality, improved remission and event-free survival rates, lower relapse rates.

For patients with chronic lymphocytic leukemia (CLL) and deletion of TP53, alemtuzumab plus methylprednisolone is a highly effective induction regimen

A subset of pediatric patients with acute lymphoblastic leukemia (ALL) who have precursor B-cell leukemia appear to have a better outcome with chemotherapy after failing remission-induction therapy.

The first Clinical Practice Guidelines in Oncology for the treatment of Acute Lymphoblastic Leukemia have been produced by the NCCN.

A study recently published in the March 12th issue of the Journal of Clinical Oncology demonstrates improved survival rates in children and adolescents diagnosed with acute lymphoblastic leukemia (ALL) during the years 1990 to 2005.

Patients with acute myeloid leukemia (AML) harboring specific combinations of mutations benefit from high-dose daunorubicin; and the majority of bone marrow cells in myelodysplastic syndromes and secondary AML are clonal and harbor multiple mutations.

The cardiac injury biomarker cardiac troponin (cTnT) and the cardiomyopathy biomarker N-terminal pro-brain natriuretic peptide (NT-proBNP) may hold promise as biomarkers of cardiotoxicity in children with high-risk acute lymphoblastic leukemia (ALL) during treatment with doxorubicin.

For patients with chronic myeloid leukemia that fails to respond to interferon alpha therapy, treatment with imatinib is associated with long-term survival of 68%, according to a study published online February 27 in Cancer.